Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Forget the share price ... follow the bouncing H2S molecule

<< Previous

Bullboard Posts

Next >>

Comment by WalkOverTheStrton Apr 23, 2021 9:16am

103 Views

Post# 33054161

RE:RE:Forget the share price ... follow the bouncing H2S molecule

Mugs - I'll ask Antibe to show us the money as in actually start a second human trial in a drug other than Oten... they can bs till pigs fly... We SHs and mgmt more importantly would be in an impressive position with HS2 validated or at least proven it is a platform (more than one human study early phase success).... Dan and mgmt failed to understand why this strategy was and is so important in current Oten partnership discussions... Tired of mgmt's bs.. deliver and execute...

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale